165 related articles for article (PubMed ID: 29563133)
41. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease.
Benson AB
Clin Cancer Res; 2007 Nov; 13(22 Pt 2):6913s-20s. PubMed ID: 18006800
[TBL] [Abstract][Full Text] [Related]
42. Comparison of two novel staging systems with the TNM system in predicting stage III colon cancer survival.
Walker R; Wood T; LeSouder E; Cleghorn M; Maganti M; MacNeill A; Quereshy FA
J Surg Oncol; 2018 Apr; 117(5):1049-1057. PubMed ID: 29473957
[TBL] [Abstract][Full Text] [Related]
43. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.
Sobrero A; Lonardi S; Rosati G; Di Bartolomeo M; Ronzoni M; Pella N; Scartozzi M; Banzi M; Zampino MG; Pasini F; Marchetti P; Cantore M; Zaniboni A; Rimassa L; Ciuffreda L; Ferrari D; Zagonel V; Maiello E; Barni S; Rulli E; Labianca R;
J Clin Oncol; 2018 May; 36(15):1478-1485. PubMed ID: 29620994
[TBL] [Abstract][Full Text] [Related]
44. The Diet of Higher Insulinemic Potential Is Not Associated with Worse Survival in Patients with Stage III Colon Cancer (Alliance).
Cheng E; Zhang S; Ou FS; Mullen B; Ng K; Saltz LB; Niedzwiecki D; Mayer RJ; Mowat RB; Whittom R; Hantel A; Benson A; Atienza D; Messino M; Kindler H; Giovannucci EL; Van Blarigan EL; Meyerhardt JA; Fuchs CS
Cancer Epidemiol Biomarkers Prev; 2020 Aug; 29(8):1692-1695. PubMed ID: 32499312
[TBL] [Abstract][Full Text] [Related]
45. Adjuvant chemotherapy with tegafur/uracil for more than 1 year improves disease-free survival for low-risk Stage II colon cancer.
Hu JM; Chou YC; Wu CC; Hsiao CW; Lee CC; Chen CT; Hu SI; Liu WT; Jao SW
J Chin Med Assoc; 2016 Sep; 79(9):477-88. PubMed ID: 27329402
[TBL] [Abstract][Full Text] [Related]
46. Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G; Zisiadis A; Dafni U; Konstantaras C; Hatzitheoharis G; Papavramidis S; Bousoulegas A; Basdanis G; Giannoulis E; Dokmetzioglou J; Katsohis C; Nenopoulou E; Karvounis N; Briassoulis E; Aravantinos G; Kosmidis P; Skarlos D; Pavlidis N
Oncology; 2000 Apr; 58(3):227-36. PubMed ID: 10765125
[TBL] [Abstract][Full Text] [Related]
47. Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans.
Aspinall SL; Good CB; Zhao X; Cunningham FE; Heron BB; Geraci M; Passero V; Stone RA; Smith KJ; Rogers R; Shields J; Sartore M; Boyle DP; Giberti S; Szymanski J; Smith D; Ha A; Sessions J; Depcinski S; Fishco S; Molina I; Lepir T; Jean C; Cruz-Diaz L; Motta J; Calderon-Vargas R; Maland J; Keefe S; Tague M; Leone A; Glovack B; Kaplan B; Cosgriff S; Kaster L; Tonnu-Mihara I; Nguyen K; Carmichael J; Clifford L; Lu K; Chatta G
BMC Cancer; 2015 Feb; 15():62. PubMed ID: 25884851
[TBL] [Abstract][Full Text] [Related]
48. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
[TBL] [Abstract][Full Text] [Related]
49. Recruitment to and pilot results of the PACES randomized trial of physical exercise during adjuvant chemotherapy for colon cancer.
van Waart H; Stuiver MM; van Harten WH; Geleijn E; de Maaker-Berkhof M; Schrama J; Geenen MM; Meerum Terwogt JM; van den Heiligenberg SM; Hellendoorn-van Vreeswijk JAJH; Sonke GS; Aaronson NK
Int J Colorectal Dis; 2018 Jan; 33(1):29-40. PubMed ID: 29124329
[TBL] [Abstract][Full Text] [Related]
50. Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial.
Karoui M; Rullier A; Luciani A; Bonnetain F; Auriault ML; Sarran A; Monges G; Trillaud H; Le Malicot K; Leroy K; Sobhani I; Bardier A; Moreau M; Brindel I; Seitz JF; Taieb J
BMC Cancer; 2015 Jul; 15():511. PubMed ID: 26156156
[TBL] [Abstract][Full Text] [Related]
51. Benefit of Postresection Adjuvant Chemotherapy for Stage III Colon Cancer in Octogenarians: Analysis of the National Cancer Database.
Bergquist JR; Thiels CA; Spindler BA; Shubert CR; Hayman AV; Kelley SR; Larson DW; Habermann EB; Pemberton JH; Mathis KL
Dis Colon Rectum; 2016 Dec; 59(12):1142-1149. PubMed ID: 27824699
[TBL] [Abstract][Full Text] [Related]
52. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
Lee AM; Shi Q; Pavey E; Alberts SR; Sargent DJ; Sinicrope FA; Berenberg JL; Goldberg RM; Diasio RB
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25381393
[TBL] [Abstract][Full Text] [Related]
53. Use and Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer: A Population-Based Study.
Booth CM; Nanji S; Wei X; Peng Y; Biagi JJ; Hanna TP; Krzyzanowska MK; Mackillop WJ
J Natl Compr Canc Netw; 2016 Jan; 14(1):47-56. PubMed ID: 26733554
[TBL] [Abstract][Full Text] [Related]
54. Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer.
Huang WY; Ho CL; Lee CC; Hsiao CW; Wu CC; Jao SW; Yang JF; Lo CH; Chen JH
PLoS One; 2017; 12(3):e0174280. PubMed ID: 28328969
[TBL] [Abstract][Full Text] [Related]
55. Disease Characteristics, Clinical Management, and Outcomes of Young Patients With Colon Cancer: A Population-based Study.
Rodriguez L; Brennan K; Karim S; Nanji S; Patel SV; Booth CM
Clin Colorectal Cancer; 2018 Dec; 17(4):e651-e661. PubMed ID: 30061036
[TBL] [Abstract][Full Text] [Related]
56. Impact of intramural and extramural vascular invasion on stage II-III colon cancer outcomes.
Leijssen LGJ; Dinaux AM; Amri R; Taylor MS; Deshpande V; Bordeianou LG; Kunitake H; Berger DL
J Surg Oncol; 2019 May; 119(6):749-757. PubMed ID: 30644557
[TBL] [Abstract][Full Text] [Related]
57. Survival paradox between stage IIB/C (T4N0) and stage IIIA (T1-2N1) colon cancer.
Kim MJ; Jeong SY; Choi SJ; Ryoo SB; Park JW; Park KJ; Oh JH; Kang SB; Park HC; Heo SC; Park JG
Ann Surg Oncol; 2015 Feb; 22(2):505-12. PubMed ID: 25145501
[TBL] [Abstract][Full Text] [Related]
58. Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance).
Wang QL; Ma C; Yuan C; Shi Q; Wolpin BM; Zhang Y; Fuchs CS; Meyer J; Zemla T; Cheng E; Kumthekar P; Guthrie KA; Couture F; Kuebler P; Kumar P; Tan B; Krishnamurthi S; Goldberg RM; Venook A; Blanke C; Shields AF; O'Reilly EM; Meyerhardt JA; Ng K
Clin Cancer Res; 2023 Jul; 29(14):2621-2630. PubMed ID: 37289007
[TBL] [Abstract][Full Text] [Related]
59. Interaction of molecular markers and physical activity on mortality in patients with colon cancer.
Meyerhardt JA; Ogino S; Kirkner GJ; Chan AT; Wolpin B; Ng K; Nosho K; Shima K; Giovannucci EL; Loda M; Fuchs CS
Clin Cancer Res; 2009 Sep; 15(18):5931-6. PubMed ID: 19723652
[TBL] [Abstract][Full Text] [Related]
60. Physical activity in recurrent colon cancer: Cancer and Leukemia Group B/SWOG 80702 (Alliance).
Brown JC; Ma C; Shi Q; Zemla T; Couture F; Kuebler P; Kumar P; Tan B; Krishnamurthi S; Chang V; Goldberg RM; Venook AP; Blanke CD; O'Reilly EM; Shields AF; Meyerhardt JA
Cancer; 2023 Dec; 129(23):3724-3734. PubMed ID: 37651160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
